KAS
CDTX

Kestra Advisory Services’s Cidara Therapeutics CDTX Stock Holding History

Kestra Advisory Services’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,825
Closed -$86.4K – 2129
2023
Q2 		$86.4K Buy
3,825
+2,518
+193% +$59.2K ﹤0.01% 2010
2023
Q1 		$33.2K Buy
+1,307
New +$37.1K ﹤0.01% 2009
2022
Q1 		– Sell
-850
Closed -$22K – 2022
2021
Q4 		$22K Sell
850
-675
-44% -$21K ﹤0.01% 1991
2021
Q3 		$68K Buy
+1,525
New +$57.9K ﹤0.01% 2077

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Kestra Advisory Services's CDTX Position: Q3 2023 in Review

Kestra Advisory Services sold out of Cidara Therapeutics (CDTX) in Q3 2023, closing a stake of 3,825 shares — an estimated $86.4K sold.

Kestra Advisory Services first reported a position in CDTX in Q3 2021 and held it in 4 quarters. The position peaked at $86.4K in Q2 2023. 52 funds tracked by Wall St. Rank hold CDTX as of Q3 2023.

  • Kestra Advisory Services reported no remaining Cidara Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Kestra Advisory Services sold 3,825 Cidara Therapeutics shares in Q3 2023, an estimated $86.4K.
  • Kestra Advisory Services first reported a position in Cidara Therapeutics in Q3 2021 and held it in 4 quarters.
  • Kestra Advisory Services's Cidara Therapeutics position peaked at $86.4K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2023.

Based on Kestra Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.